Does the media favor FLNA or LENZ?

In the previous week, LENZ Therapeutics had 1 more articles in the media than Cassava Sciences. MarketBeat recorded 8 mentions for LENZ Therapeutics and 7 mentions for Cassava Sciences. Cassava Sciences' average media sentiment score of 0.31 beat LENZ Therapeutics' score of 0.22 indicating that Cassava Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cassava Sciences 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral LENZ Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is FLNA or VTVT more profitable?

vTv Therapeutics' return on equity of -6.27% beat Cassava Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Cassava Sciences N/A -58.78% -36.74% vTv Therapeutics N/A -6.27% -5.06%

Does the media prefer FLNA or VTVT?

In the previous week, Cassava Sciences had 5 more articles in the media than vTv Therapeutics. MarketBeat recorded 7 mentions for Cassava Sciences and 2 mentions for vTv Therapeutics. vTv Therapeutics' average media sentiment score of 0.89 beat Cassava Sciences' score of 0.31 indicating that vTv Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cassava Sciences 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral vTv Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, AARD or FLNA?

Aardvark Therapeutics is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aardvark Therapeutics N/A N/A -$57.59M -$3.21 N/A Cassava Sciences N/A N/A -$90.97M -$0.87 N/A

Is AARD or FLNA more profitable?

Cassava Sciences' return on equity of -58.78% beat Aardvark Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aardvark Therapeutics N/A -71.54% -64.94% Cassava Sciences N/A -58.78% -36.74%

Does the media refer more to AARD or FLNA?

In the previous week, Aardvark Therapeutics had 23 more articles in the media than Cassava Sciences. MarketBeat recorded 30 mentions for Aardvark Therapeutics and 7 mentions for Cassava Sciences. Cassava Sciences' average media sentiment score of 0.31 beat Aardvark Therapeutics' score of 0.11 indicating that Cassava Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aardvark Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 25 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cassava Sciences 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is MIST or FLNA more profitable?

Cassava Sciences' return on equity of -58.78% beat Milestone Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Milestone Pharmaceuticals N/A -288.33% -58.27% Cassava Sciences N/A -58.78% -36.74%

Does the media refer more to MIST or FLNA?

In the previous week, Cassava Sciences had 3 more articles in the media than Milestone Pharmaceuticals. MarketBeat recorded 7 mentions for Cassava Sciences and 4 mentions for Milestone Pharmaceuticals. Milestone Pharmaceuticals' average media sentiment score of 0.79 beat Cassava Sciences' score of 0.31 indicating that Milestone Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Milestone Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cassava Sciences 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate FLNA or RFL?

Cassava Sciences currently has a consensus target price of $5.00, indicating a potential upside of 568.36%. Given Cassava Sciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe Cassava Sciences is more favorable than Rafael. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cassava Sciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Rafael 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is FLNA or RFL more profitable?

Cassava Sciences has a net margin of 0.00% compared to Rafael's net margin of -3,321.74%. Rafael's return on equity of -41.27% beat Cassava Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Cassava Sciences N/A -58.78% -36.74% Rafael -3,321.74% -41.27% -35.32%

Cassava Sciences (FLNA) Competitors

$0.75 -0.02 (-3.20%)

As of 09/25/2026 04:00 PM Eastern

Compare

FLNA vs. LENZ, VTVT, AARD, MIST, and RFL

Should you buy Cassava Sciences stock or one of its competitors? Cassava Sciences's main competitors and comparable companies include LENZ Therapeutics (LENZ), vTv Therapeutics (VTVT), Aardvark Therapeutics (AARD), Milestone Pharmaceuticals (MIST), and Rafael (RFL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Cassava Sciences compare to LENZ Therapeutics?

Cassava Sciences (NASDAQ:FLNA) and LENZ Therapeutics (NASDAQ:LENZ) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, media sentiment, risk and dividends.

38.1% of Cassava Sciences shares are owned by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are owned by institutional investors. 4.6% of Cassava Sciences shares are owned by company insiders. Comparatively, 8.3% of LENZ Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Cassava Sciences presently has a consensus target price of $5.00, indicating a potential upside of 568.36%. LENZ Therapeutics has a consensus target price of $28.80, indicating a potential upside of 636.57%. Given LENZ Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe LENZ Therapeutics is more favorable than Cassava Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
LENZ Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Cassava Sciences has a net margin of 0.00% compared to LENZ Therapeutics' net margin of -586.74%. LENZ Therapeutics' return on equity of -53.39% beat Cassava Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cassava Sciences	N/A	-58.78%	-36.74%
LENZ Therapeutics	-586.74%	-53.39%	-49.14%

In the previous week, LENZ Therapeutics had 1 more articles in the media than Cassava Sciences. MarketBeat recorded 8 mentions for LENZ Therapeutics and 7 mentions for Cassava Sciences. Cassava Sciences' average media sentiment score of 0.31 beat LENZ Therapeutics' score of 0.22 indicating that Cassava Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cassava Sciences	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
LENZ Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cassava Sciences has a beta of -0.69, indicating that its stock price is 169% less volatile than the broader market. Comparatively, LENZ Therapeutics has a beta of 0.66, indicating that its stock price is 34% less volatile than the broader market.

LENZ Therapeutics has higher revenue and earnings than Cassava Sciences. LENZ Therapeutics is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cassava Sciences	N/A	N/A	-$90.97M	-$0.87	N/A
LENZ Therapeutics	$19.09M	6.44	-$82.13M	-$4.09	N/A

Summary

LENZ Therapeutics beats Cassava Sciences on 10 of the 15 factors compared between the two stocks.

How does Cassava Sciences compare to vTv Therapeutics?

Cassava Sciences (NASDAQ:FLNA) and vTv Therapeutics (NASDAQ:VTVT) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, media sentiment, earnings, dividends and institutional ownership.

38.1% of Cassava Sciences shares are held by institutional investors. Comparatively, 17.5% of vTv Therapeutics shares are held by institutional investors. 4.6% of Cassava Sciences shares are held by company insiders. Comparatively, 6.0% of vTv Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Cassava Sciences presently has a consensus target price of $5.00, suggesting a potential upside of 568.36%. vTv Therapeutics has a consensus target price of $55.83, suggesting a potential upside of 84.82%. Given Cassava Sciences' higher probable upside, equities analysts plainly believe Cassava Sciences is more favorable than vTv Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
vTv Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

In the previous week, Cassava Sciences had 5 more articles in the media than vTv Therapeutics. MarketBeat recorded 7 mentions for Cassava Sciences and 2 mentions for vTv Therapeutics. vTv Therapeutics' average media sentiment score of 0.89 beat Cassava Sciences' score of 0.31 indicating that vTv Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cassava Sciences	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
vTv Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

vTv Therapeutics' return on equity of -6.27% beat Cassava Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cassava Sciences	N/A	-58.78%	-36.74%
vTv Therapeutics	N/A	-6.27%	-5.06%

vTv Therapeutics has higher revenue and earnings than Cassava Sciences. vTv Therapeutics is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cassava Sciences	N/A	N/A	-$90.97M	-$0.87	N/A
vTv Therapeutics	$1.02M	116.69	-$26.97M	-$1.06	N/A

Cassava Sciences has a beta of -0.69, suggesting that its share price is 169% less volatile than the broader market. Comparatively, vTv Therapeutics has a beta of 0.29, suggesting that its share price is 71% less volatile than the broader market.

Summary

vTv Therapeutics beats Cassava Sciences on 10 of the 15 factors compared between the two stocks.

How does Cassava Sciences compare to Aardvark Therapeutics?

Aardvark Therapeutics (NASDAQ:AARD) and Cassava Sciences (NASDAQ:FLNA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, media sentiment, profitability, earnings and risk.

In the previous week, Aardvark Therapeutics had 23 more articles in the media than Cassava Sciences. MarketBeat recorded 30 mentions for Aardvark Therapeutics and 7 mentions for Cassava Sciences. Cassava Sciences' average media sentiment score of 0.31 beat Aardvark Therapeutics' score of 0.11 indicating that Cassava Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aardvark Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	25 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cassava Sciences	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cassava Sciences' return on equity of -58.78% beat Aardvark Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aardvark Therapeutics	N/A	-71.54%	-64.94%
Cassava Sciences	N/A	-58.78%	-36.74%

38.1% of Cassava Sciences shares are held by institutional investors. 17.8% of Aardvark Therapeutics shares are held by company insiders. Comparatively, 4.6% of Cassava Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Aardvark Therapeutics presently has a consensus price target of $15.33, indicating a potential upside of 203.03%. Cassava Sciences has a consensus price target of $5.00, indicating a potential upside of 568.36%. Given Cassava Sciences' higher probable upside, analysts clearly believe Cassava Sciences is more favorable than Aardvark Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aardvark Therapeutics	2 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.42
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Aardvark Therapeutics is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aardvark Therapeutics	N/A	N/A	-$57.59M	-$3.21	N/A
Cassava Sciences	N/A	N/A	-$90.97M	-$0.87	N/A

Aardvark Therapeutics has a beta of 3.74, indicating that its share price is 274% more volatile than the broader market. Comparatively, Cassava Sciences has a beta of -0.69, indicating that its share price is 169% less volatile than the broader market.

Summary

Aardvark Therapeutics and Cassava Sciences tied by winning 7 of the 14 factors compared between the two stocks.

How does Cassava Sciences compare to Milestone Pharmaceuticals?

Milestone Pharmaceuticals (NASDAQ:MIST) and Cassava Sciences (NASDAQ:FLNA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, risk, earnings, dividends and media sentiment.

Milestone Pharmaceuticals has higher revenue and earnings than Cassava Sciences. Milestone Pharmaceuticals is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Milestone Pharmaceuticals	$1.55M	63.33	-$63.06M	-$0.69	N/A
Cassava Sciences	N/A	N/A	-$90.97M	-$0.87	N/A

Milestone Pharmaceuticals has a beta of 0.98, indicating that its stock price is 2% less volatile than the broader market. Comparatively, Cassava Sciences has a beta of -0.69, indicating that its stock price is 169% less volatile than the broader market.

In the previous week, Cassava Sciences had 3 more articles in the media than Milestone Pharmaceuticals. MarketBeat recorded 7 mentions for Cassava Sciences and 4 mentions for Milestone Pharmaceuticals. Milestone Pharmaceuticals' average media sentiment score of 0.79 beat Cassava Sciences' score of 0.31 indicating that Milestone Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Milestone Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cassava Sciences	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cassava Sciences' return on equity of -58.78% beat Milestone Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Milestone Pharmaceuticals	N/A	-288.33%	-58.27%
Cassava Sciences	N/A	-58.78%	-36.74%

Milestone Pharmaceuticals currently has a consensus target price of $6.40, indicating a potential upside of 711.77%. Cassava Sciences has a consensus target price of $5.00, indicating a potential upside of 568.36%. Given Milestone Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Milestone Pharmaceuticals is more favorable than Cassava Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Milestone Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. Comparatively, 38.1% of Cassava Sciences shares are owned by institutional investors. 5.0% of Milestone Pharmaceuticals shares are owned by insiders. Comparatively, 4.6% of Cassava Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Milestone Pharmaceuticals beats Cassava Sciences on 11 of the 15 factors compared between the two stocks.

How does Cassava Sciences compare to Rafael?

Cassava Sciences (NASDAQ:FLNA) and Rafael (NYSE:RFL) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings, valuation and media sentiment.

38.1% of Cassava Sciences shares are owned by institutional investors. Comparatively, 11.3% of Rafael shares are owned by institutional investors. 4.6% of Cassava Sciences shares are owned by company insiders. Comparatively, 32.9% of Rafael shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Cassava Sciences had 7 more articles in the media than Rafael. MarketBeat recorded 7 mentions for Cassava Sciences and 0 mentions for Rafael. Cassava Sciences' average media sentiment score of 0.31 beat Rafael's score of 0.00 indicating that Cassava Sciences is being referred to more favorably in the media.

Company	Overall Sentiment
Cassava Sciences	Neutral
Rafael	Neutral

Cassava Sciences has a beta of -0.69, suggesting that its share price is 169% less volatile than the broader market. Comparatively, Rafael has a beta of 0.4, suggesting that its share price is 60% less volatile than the broader market.

Cassava Sciences currently has a consensus target price of $5.00, indicating a potential upside of 568.36%. Given Cassava Sciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe Cassava Sciences is more favorable than Rafael.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Rafael	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Cassava Sciences has a net margin of 0.00% compared to Rafael's net margin of -3,321.74%. Rafael's return on equity of -41.27% beat Cassava Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cassava Sciences	N/A	-58.78%	-36.74%
Rafael	-3,321.74%	-41.27%	-35.32%

Rafael has higher revenue and earnings than Cassava Sciences. Rafael is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cassava Sciences	N/A	N/A	-$90.97M	-$0.87	N/A
Rafael	$920K	110.39	-$30.52M	-$0.68	N/A

Summary

Cassava Sciences beats Rafael on 8 of the 15 factors compared between the two stocks.

Get Cassava Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FLNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FLNA vs. The Competition

Export

Metric	Cassava Sciences	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$37.33M	$12.64B	$7.29B	$13.12B
Dividend Yield	N/A	2.63%	2.52%	13.50%
P/E Ratio	-0.86	797.38	275.84	25.78
Price / Sales	N/A	758.81	618.88	84.19
Price / Cash	N/A	91.64	79.23	52.93
Price / Book	0.49	10.54	10.44	6.30
Net Income	-$90.97M	$2.85B	$3.51B	$360.35M
7 Day Performance	3.04%	-1.09%	-1.31%	-0.23%
1 Month Performance	-19.07%	-3.10%	-4.72%	-3.87%
1 Year Performance	-74.98%	0.98%	14.97%	5.38%

Cassava Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FLNA Cassava Sciences	1.8014 of 5 stars	$0.75 -3.2%	$5.00 +568.4%	-75.9%	$37.33M	N/A	N/A	30	Analyst Upgrade
LENZ LENZ Therapeutics	2.9724 of 5 stars	$4.52 flat	$28.80 +537.2%	-90.2%	$141.96M	$19.09M	N/A	110	News Coverage
VTVT vTv Therapeutics	3.1157 of 5 stars	$32.05 +0.3%	$55.83 +74.2%	+33.9%	$126.75M	$1.02M	N/A	9	Positive News
AARD Aardvark Therapeutics	3.6614 of 5 stars	$5.60 +9.1%	$15.33 +174.1%	-60.1%	$122.64M	N/A	N/A	18	Trending News Analyst Forecast
MIST Milestone Pharmaceuticals	2.4655 of 5 stars	$0.96 -1.8%	$6.40 +565.3%	-60.0%	$119.27M	$1.55M	N/A	30

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FLNA) was last updated on 9/26/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cassava Sciences (FLNA) Competitors

FLNA vs. LENZ, VTVT, AARD, MIST, and RFL

How does Cassava Sciences compare to LENZ Therapeutics?

Summary

How does Cassava Sciences compare to vTv Therapeutics?

Summary

How does Cassava Sciences compare to Aardvark Therapeutics?

Summary

How does Cassava Sciences compare to Milestone Pharmaceuticals?

Summary

How does Cassava Sciences compare to Rafael?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FLNA vs. The Competition

Cassava Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cassava Sciences (FLNA) Competitors

FLNA vs. LENZ, VTVT, AARD, MIST, and RFL

How does Cassava Sciences compare to LENZ Therapeutics?

Do institutionals and insiders believe in FLNA or LENZ?

Do analysts recommend FLNA or LENZ?

Is FLNA or LENZ more profitable?

Does the media favor FLNA or LENZ?

Which has more risk & volatility, FLNA or LENZ?

Which has better valuation & earnings, FLNA or LENZ?

Summary

How does Cassava Sciences compare to vTv Therapeutics?

Do institutionals & insiders have more ownership in FLNA or VTVT?

Do analysts prefer FLNA or VTVT?

Does the media prefer FLNA or VTVT?

Is FLNA or VTVT more profitable?

Which has higher earnings and valuation, FLNA or VTVT?

Which has more risk & volatility, FLNA or VTVT?

Summary

How does Cassava Sciences compare to Aardvark Therapeutics?

Does the media refer more to AARD or FLNA?

Is AARD or FLNA more profitable?

Do institutionals and insiders have more ownership in AARD or FLNA?

Do analysts rate AARD or FLNA?

Which has better valuation and earnings, AARD or FLNA?

Which has more risk and volatility, AARD or FLNA?

Summary

How does Cassava Sciences compare to Milestone Pharmaceuticals?

Which has higher earnings & valuation, MIST or FLNA?

Which has more volatility and risk, MIST or FLNA?

Does the media refer more to MIST or FLNA?

Is MIST or FLNA more profitable?

Do analysts rate MIST or FLNA?

Do institutionals & insiders have more ownership in MIST or FLNA?

Summary

How does Cassava Sciences compare to Rafael?

Do insiders and institutionals have more ownership in FLNA or RFL?

Does the media prefer FLNA or RFL?

Which has more risk and volatility, FLNA or RFL?

Do analysts rate FLNA or RFL?

Is FLNA or RFL more profitable?

Which has stronger earnings and valuation, FLNA or RFL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FLNA vs. The Competition

Cassava Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools